Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1999 Mar 9;160(5):685–690.

Prostate cancer: 12. The economic burden

S A Grover 1, H Zowall 1, L Coupal 1, M D Krahn 1
PMCID: PMC1230115  PMID: 10102004

Full Text

The Full Text of this article is available as a PDF (121.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett C. L., Matchar D., McCrory D., McLeod D. G., Crawford E. D., Hillner B. E. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer. 1996 May 1;77(9):1854–1861. doi: 10.1002/(SICI)1097-0142(19960501)77:9<1854::AID-CNCR15>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  2. Bloomfield D. J., Krahn M. D., Neogi T., Panzarella T., Smith T. J., Warde P., Willan A. R., Ernst S., Moore M. J., Neville A. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol. 1998 Jun;16(6):2272–2279. doi: 10.1200/JCO.1998.16.6.2272. [DOI] [PubMed] [Google Scholar]
  3. Bunting P. S., Miyazaki J. H., Goel V. Laboratory survey of prostate specific antigen testing in Ontario. Clin Biochem. 1998 Feb;31(1):47–49. doi: 10.1016/s0009-9120(97)00141-0. [DOI] [PubMed] [Google Scholar]
  4. Cantor S. B., Spann S. J., Volk R. J., Cardenas M. P., Warren M. M. Prostate cancer screening: a decision analysis. J Fam Pract. 1995 Jul;41(1):33–41. [PubMed] [Google Scholar]
  5. Carlsson P., Hjertberg H., Jönsson B., Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol. 1989;23(2):93–96. doi: 10.3109/00365598909180819. [DOI] [PubMed] [Google Scholar]
  6. Coley C. M., Barry M. J., Fleming C., Fahs M. C., Mulley A. G. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997 Mar 15;126(6):468–479. doi: 10.7326/0003-4819-126-6-199703150-00010. [DOI] [PubMed] [Google Scholar]
  7. Cooper B. S., Rice D. P. The economic cost of illness revisited. Soc Secur Bull. 1976 Feb;39(2):21–36. [PubMed] [Google Scholar]
  8. Denmeade S. R., Isaacs J. T. Prostate cancer: where are we and where are we going? Br J Urol. 1997 Mar;79 (Suppl 1):2–7. doi: 10.1111/j.1464-410x.1997.tb00794.x. [DOI] [PubMed] [Google Scholar]
  9. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics. 1992 Jul;2(1):1–4. doi: 10.2165/00019053-199202010-00001. [DOI] [PubMed] [Google Scholar]
  10. Epstein J. I., Walsh P. C., Sanfilippo F. Clinical and cost impact of second-opinion pathology. Review of prostate biopsies prior to radical prostatectomy. Am J Surg Pathol. 1996 Jul;20(7):851–857. doi: 10.1097/00000478-199607000-00008. [DOI] [PubMed] [Google Scholar]
  11. Forman H. P., Fox L. A., Glazer H. S., McClennan B. L., Anderson D. C., Sagel S. S. Chest radiography in patients with early stage prostatic carcinoma. Effect on treatment planning and cost analysis. Chest. 1994 Oct;106(4):1036–1041. doi: 10.1378/chest.106.4.1036. [DOI] [PubMed] [Google Scholar]
  12. Forman H. P., Heiken J. P., Brink J. A., Glazer H. S., Fox L. A., McClennan B. L. CT screening for comorbid disease in patients with prostatic carcinoma: is it cost-effective? AJR Am J Roentgenol. 1994 May;162(5):1125–1130. doi: 10.2214/ajr.162.5.8165996. [DOI] [PubMed] [Google Scholar]
  13. Gurwitz J. H., Avorn J., Bohn R. L., Glynn R. J., Monane M., Mogun H. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994 Sep 14;272(10):781–786. [PubMed] [Google Scholar]
  14. Hillner B. E., McLeod D. G., Crawford E. D., Bennett C. L. Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer. Urology. 1995 Apr;45(4):633–640. doi: 10.1016/S0090-4295(99)80055-7. [DOI] [PubMed] [Google Scholar]
  15. Hodgson T. A. Cost of illness studies: no aid to decision making? Comments on the second opinion by Shiell et al. (Health Policy, 8(1987) 317-323). Health Policy. 1989;11(1):57–60. doi: 10.1016/0168-8510(89)90055-9. [DOI] [PubMed] [Google Scholar]
  16. Hodgson T. A. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res. 1983;4:129–164. [PubMed] [Google Scholar]
  17. Jones G. W., Mettlin C., Murphy G. P., Guinan P., Herr H. W., Hussey D. H., Chmiel J. S., Fremgen A. M., Clive R. E., Zuber-Ocwieja K. E. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg. 1995 May;180(5):545–554. [PubMed] [Google Scholar]
  18. Koopmanschap M. A., van Roijen L., Bonneux L., Barendregt J. J. Current and future costs of cancer. Eur J Cancer. 1994;30A(1):60–65. doi: 10.1016/s0959-8049(05)80020-6. [DOI] [PubMed] [Google Scholar]
  19. Levy I. G., Iscoe N. A., Klotz L. H. Prostate cancer: 1. The descriptive epidemiology in Canada. CMAJ. 1998 Sep 8;159(5):509–513. [PMC free article] [PubMed] [Google Scholar]
  20. Licht M. R., Klein E. A. Early hospital discharge after radical retropubic prostatectomy: impact on cost and complication rate. Urology. 1994 Nov;44(5):700–704. doi: 10.1016/s0090-4295(94)80211-4. [DOI] [PubMed] [Google Scholar]
  21. Littrup P. J., Goodman A. C., Mettlin C. J. The benefit and cost of prostate cancer early detection. The Investigators of the American Cancer Society-National Prostate Cancer Detection Project. CA Cancer J Clin. 1993 May-Jun;43(3):134–149. doi: 10.3322/canjclin.43.3.134. [DOI] [PubMed] [Google Scholar]
  22. Lu-Yao G. L., McLerran D., Wasson J., Wennberg J. E. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2633–2636. doi: 10.1001/jama.269.20.2633. [DOI] [PubMed] [Google Scholar]
  23. Lu-Yao G. L., Potosky A. L., Albertsen P. C., Wasson J. H., Barry M. J., Wennberg J. E. Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst. 1996 Feb 21;88(3-4):166–173. doi: 10.1093/jnci/88.3-4.166. [DOI] [PubMed] [Google Scholar]
  24. McEwan A. J., Amyotte G. A., McGowan D. G., MacGillivray J. A., Porter A. T. A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun. 1994 Jul;15(7):499–504. doi: 10.1097/00006231-199407000-00002. [DOI] [PubMed] [Google Scholar]
  25. Mettlin C., Jones G. W., Murphy G. P. Trends in prostate cancer care in the United States, 1974-1990: observations from the patient care evaluation studies of the American College of Surgeons Commission on Cancer. CA Cancer J Clin. 1993 Mar-Apr;43(2):83–91. doi: 10.3322/canjclin.43.2.83. [DOI] [PubMed] [Google Scholar]
  26. Morrison H. I., MacNeill I. B., Miller D., Levy I., Xie L., Mao Y. The impending Canadian prostate cancer epidemic. Can J Public Health. 1995 Jul-Aug;86(4):274–278. [PubMed] [Google Scholar]
  27. O'Brien B., Viramontes J. L. Willingness to pay: a valid and reliable measure of health state preference? Med Decis Making. 1994 Jul-Sep;14(3):289–297. doi: 10.1177/0272989X9401400311. [DOI] [PubMed] [Google Scholar]
  28. Optenberg S. A., Thompson I. M. Economics of screening for carcinoma of the prostate. Urol Clin North Am. 1990 Nov;17(4):719–737. [PubMed] [Google Scholar]
  29. Otnes B., Harvei S., Fosså S. D. The burden of prostate cancer from diagnosis until death. Br J Urol. 1995 Nov;76(5):587–594. doi: 10.1111/j.1464-410x.1995.tb07783.x. [DOI] [PubMed] [Google Scholar]
  30. Perrotti M., Gentle D. L., Barada J. H., Wilbur H. J., Kaufman R. P., Jr Mini-laparotomy pelvic lymph node dissection minimizes morbidity, hospitalization and cost of pelvic lymph node dissection. J Urol. 1996 Mar;155(3):986–988. [PubMed] [Google Scholar]
  31. Robinson J. C. Philosophical origins of the economic valuation of life. Milbank Q. 1986;64(1):133–155. [PubMed] [Google Scholar]
  32. Taplin S. H., Barlow W., Urban N., Mandelson M. T., Timlin D. J., Ichikawa L., Nefcy P. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995 Mar 15;87(6):417–426. doi: 10.1093/jnci/87.6.417. [DOI] [PubMed] [Google Scholar]
  33. To T., Iscoe N., Klotz L., Naylor C. D. Orchidectomy and hormonal therapy of prostate cancer. Can J Urol. 1995 Jan;2(1):109–115. [PubMed] [Google Scholar]
  34. Wasson J. H., Cushman C. C., Bruskewitz R. C., Littenberg B., Mulley A. G., Jr, Wennberg J. E. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med. 1993 May;2(5):487–493. doi: 10.1001/archfami.2.5.487. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES